日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Long-acting GIPR agonist LY3537021 reduces body weight and fasting blood glucose in patients with T2D: Preclinical development and phase 1 randomized ascending dose studies

长效GIPR激动剂LY3537021可降低2型糖尿病患者的体重和空腹血糖:临床前开发和1期随机递增剂量研究

Roell, William; Alsina-Fernandez, Jorge; Qu, Hongchang; Coskun, Tamer; Benson, Charles; Haupt, Axel; Kelly, Ronan P; O'Farrell, Libbey; Sloop, Kyle W; Steele, James P; Ficorilli, James; Regmi, Ajit; Rettiganti, Mallikarjuna; Urva, Shweta; Mather, Kieren J; Pratt, Edward

Eloralintide, a selective, long-acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept

埃洛拉林肽,一种选择性长效胰淀素受体激动剂,用于治疗肥胖症:I期概念验证

Bhattachar, Shobha; Tham, Lai San; Tidemann-Miller, Beth; Ibriga, Hilda; Qu, Hongchang; Briere, Daniel A; Haupt, Axel; Mather, Kieren J; Pratt, Edward

Treatment with orforglipron, an oral glucagon like peptide-1 receptor agonist, is associated with improvements of CV risk biomarkers in participants with type 2 diabetes or obesity without diabetes

使用口服胰高血糖素样肽-1受体激动剂奥福格列酮治疗,可改善2型糖尿病或非糖尿病肥胖患者的心血管风险生物标志物。

Wharton, Sean; Rosenstock, Julio; Konige, Manige; Lin, Yanzhu; Duffin, Kevin; Wilson, Jonathan; Banerjee, Hiya; Pirro, Valentina; Kazda, Christof; Mather, Kieren

The Disposition Index in Autoantibody-Positive Individuals at Risk for Type 1 Diabetes

自身抗体阳性且有患1型糖尿病风险的个体的处置指数

Ismail, Heba M; Cuthbertson, David; Galderisi, Alfonso; Libman, Ingrid; Jacobsen, Laura; Moran, Antoinette; Petrelli, Alessandra; Atkinson, Mark; Redondo, Maria J; Hannon, Tamara; Mather, Kieren J; Sosenko, Jay M

Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept

埃洛拉林肽(LY3841136),一种用于治疗肥胖症的新型胰淀素受体激动剂:从发现到临床概念验证

Briere, Daniel A; Qu, Hongchang; Lansu, Katherine; He, Minxia Michelle; Moyers, Julie S; Coskun, Tamer; Long, Annie; Allen, Dawn; O'Farrell, Libbey; Bowen, Breanna; Pratt, Edward; Tidemann-Miller, Beth; Tham, Lai San; Ibriga, Hilda; Alsina-Fernandez, Jorge; Mather, Kieren J; Haupt, Axel; Bhattachar, Shobha N

Mazdutide reduces body weight in adults with overweight or obesity: A high-dose Phase 1 trial

马度肽可降低超重或肥胖成年人的体重:一项高剂量 I 期试验

Bhattachar, Shobha N; Tham, Lai San; Li, Yan; Chua, Laiyi; Ng, Shu Xuan; Tang, Yuanyuan; Ibriga, Hilda; Ni, Wei; Gurbuz, Sirel; Mather, Kieren J; Thomas, Melissa K

Selective Collection of Exhaled Breath Condensate for Noninvasive Screening of Breath Glucose

选择性收集呼出气冷凝液用于无创筛查呼气葡萄糖

Desai, Aditya; Tankasala, Divya; Ng, Gabriel P; Thakkar, Pankti; Hoilett, Orlando S; Mather, Kieren J; Linnes, Jacqueline C

Prevalence of complications and comorbidities associated with obesity: a health insurance claims analysis

肥胖相关并发症和合并症的患病率:一项健康保险索赔分析

Bae, Jay P; Nelson, David R; Boye, Kristina S; Mather, Kieren J

A Post-Hoc Analysis of Depressive Disorders in Patients with Type 2 Diabetes

对2型糖尿病患者抑郁症的事后分析

Pillay, Yegan; Hornsby, W Guyton Jr; Saha, Chandan K; Shubrook, Jay; Crick, Kent A; Yang, Ziyi; Mather, Kieren; de Groot, Mary

Relationship Between Metabolic and Histological Responses in People With Metabolic Dysfunction- Associated Steatohepatitis With and Without Type 2 Diabetes: Participant-Level Exploratory Analysis of the SYNERGY-NASH Trial With Tirzepatide

代谢功能障碍相关性脂肪性肝炎患者(伴或不伴2型糖尿病)代谢反应与组织学反应的关系:SYNERGY-NASH试验中替拉帕肽治疗的参与者水平探索性分析

Caussy, Cyrielle; Cusi, Kenneth; Rosenstock, Julio; Bugianesi, Elisabetta; Thomas, Melissa K; Tang, Yuanyuan; Mather, Kieren J; Loomba, Rohit; Sanyal, Arun J; Hartman, Mark L